Subscribe to Search results

The assessor for an application for a variation to Hemofil product licence noted that there was no evidence to confirm that AIDS was a viral mediated infection and the addition of heat treatment would destroy about 20% of the coagulant activity yield.

Published on:

A.W. Barrell (Travenol) wrote to Professor Bloom, other haemophilia centre directors and the DHSS to say that Travenol could not give an assurance that the heat treated product eliminated the risk of transmission of AIDS since the causative agent for AIDS had not been identified.

Published on:

Travenol applied for a UK Product Licence for Hemofil-T (Antihaemophilic Factor Human Method Four Heat Treated).

Published on:

In a letter to Dr Thomas (NIBSC), Pat Thomas (Hoechst) indicated that Hoechst intended to introduce Haemate P to the market, approximately two years after obtaining a product licence.

Published on:

In an assessment of Haemate P (Heat Treated Factor 8), Dr Fowler concluded that it was probable that Hepatitis B would be less likely with the heat-treated product than with comparable untreated products.

Published on:

A licence was granted for Haemate P (Heat Treated Factor 8), produced by Behringwerke, subject to a number of conditions.

Published on:

An application for high potency Factorate from Armour was declined in July 1984 on the grounds of safety, quality and efficacy.

Published on:

The CDC published a report on their study conducted on a heat-treated product produced by Cutter which recorded that the preliminary evidence of the effects of heat treatment was that it reduced the potential for transmission of the AIDS virus.

Published on:

At a meeting of the CSM(B), Dr Smith reported that preliminary evidence suggested that heat treatment would reduce the potential of transmitting AIDs via blood products.

Published on:

In a letter to R Nicholson (Immuno), M E Duncan (DHSS) confirmed that the Licensing Authority encouraged pharmaceutical companies to use a dry heat treatment process.

Published on:

An internal Cutter memo stated that AIDs had caused a virtual panic in the Department of Health, and that the Department had blocked every application for registration of heat-treated Factor 8 for a year.

Published on:

The DHSS began to collect data on the ability of heat-treated blood products to inactivate HIV.

Published on:

Immuno made an application for Kryobulin TIM 2.

Published on:

Dr Frances Rotblat (DHSS) was recorded as having told Cutter that it was extremely rare for the yellow card system for reporting adverse reactions to be used for hepatitis in blood products.

Published on:

Between 1970 and 1995 the Yellow Card reporting scheme for adverse drug reactions was limited to medical practitioners.

Published on:

In an affidavit, Professor Adolf Asscher stated that there was an established process of investigating reports of serious adverse reactions.

Published on:

The British Pharmacopoeia did not contain references the risk of AIDs associated with the use of commercial factor concentrates between 1983 and 1985.

Published on:

The CSM declined to grant a licence for Serum Cholinesterase.

Published on:

In a memo to Mr Wrigglesworth, Dr Fowler recorded the results of the FDA meeting held on 19 July 1983. The possibility of banning all products made before the FDA's March 1983 Regulations was rejected.

Published on:

A. W. Burrell (Managing Director, Travenol) wrote a letter to Dr Walford advising her that "well before" the FDA's 24 March recommendation, Hyland had taken steps to introduce screening procedures designed to eliminate high-risk donors.

Published on: